Tatva Chintan Pharma Chem Ltd announced its Q2 and H1 financial results for FY25, reporting a 14% increase in revenue from operations to ₹1,055 million in Q2FY25 and a 10% increase to ₹2,110 million for H1FY25, with PAT rising by 109% in Q2FY25 and 74% for H1FY25.